As previously reported, Oppenheimer analyst Rupesh Parikh downgraded Prestige Consumer (PBH) to Perform from Outperform following the company’s softer than expected Q4 results and weaker initial FY26 guidance. Oppenheimer expected a below consensus guide, but this was worse than it envisioned. With management now digesting two acquisitions, higher leverage, and a more uncertain consumer backdrop, the firm sees a weaker outperformance case.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer downgraded to Perform from Outperform at Oppenheimer
- Prestige Consumer Healthcare Issues Fiscal 2026 Results, Outlook
- Prestige Consumer Healthcare: Buy Rating Reaffirmed Despite Soft Outlook, with Acquisitions and Undervalued Earnings Power Seen as Upside Drivers
- Prestige Consumer reports Q4 adjusted EPS $1.23, consensus $1.39
- Prestige Consumer to acquire LaCorium Health for $150M in cash
